High Risk Smoldering Multiple Myeloma clinical trials

Explore recruiting high risk smoldering multiple myeloma clinical trials.

Recruiting high risk smoldering multiple myeloma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

High Risk Smoldering Multiple Myeloma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A multi-center, open-label, phase 2 study of Elranatamab in patients with high-risk smoldering multiple myeloma

France, Greece, Netherlands, Norway, Finland, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3 randomized, open-label, multicenter study of isatuximab (SAR650984) in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma

Denmark, Germany, Hungary, Greece, Norway, Italy +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase II Open-Label, Single Arm, Multicenter Study of Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma (GEM-CAR-HiRiSMM)

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma

Denmark, Sweden, Czechia, Belgium, Hungary, Spain +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

HOVON 147 MM: Carfilzomib, Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone in High- Risk Smoldering Multiple Myeloma: A Randomized Phase 2 Study.

Norway, Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

PHASE 2 DOSE-RANGING AND INTERCEPTION STUDY OF LINVOSELTAMAB IN PATIENTS WITH HIGH-RISK MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE OR NON-HIGH-RISK SMOLDERING MULTIPLE MYELOMA

Spain, Ireland, Belgium, France, Italy, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

High Risk Smoldering Multiple Myeloma trials by city

High Risk Smoldering Multiple Myeloma in Toronto High Risk Smoldering Multiple Myeloma in Vancouver High Risk Smoldering Multiple Myeloma in Montreal High Risk Smoldering Multiple Myeloma in Calgary High Risk Smoldering Multiple Myeloma in Edmonton High Risk Smoldering Multiple Myeloma in Ottawa High Risk Smoldering Multiple Myeloma in Winnipeg High Risk Smoldering Multiple Myeloma in Quebec City High Risk Smoldering Multiple Myeloma in Hamilton High Risk Smoldering Multiple Myeloma in Kitchener High Risk Smoldering Multiple Myeloma in London High Risk Smoldering Multiple Myeloma in Halifax High Risk Smoldering Multiple Myeloma in New York High Risk Smoldering Multiple Myeloma in Los Angeles High Risk Smoldering Multiple Myeloma in Chicago High Risk Smoldering Multiple Myeloma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease